However , it can significantly decrease postintervention and reduction data of FPG , FI , HbA1c , and HOMA-IR .
Heterogeneity was eliminated by subgroup analysis according to baseline BMI .
There was no significant difference in the amelioration of QUICKI between the ITC and control groups .
However , the difference was statistically significant and the heterogeneity was eliminated after subgroup analysis according to intakes of ITC .
Conclusion Supplementation of ITC can ameliorate IR in T2DM , especially in obese T2DM patients , but the effects are controversial in obese patients
Background Insulin resistance ( IR ) is a physiological condition related to type 2 diabetes mellitus ( T2DM ) and obesity , which is associated with high blood insulin and glucose .
Inulin-type carbohydrate ( ITC ) is a kind of fermentable fructan that can reduce glucose and ameliorate IR in an animal model , but the effect in clinical trials is controversial .
Objective The authors conducted a systematic literature review to evaluate the effect of ITC supplementation in ameliorating IR in T2DM and obese patients .
Consumption of fructooligosaccharides does not favorably affect blood glucose and serum lipid concentrations in patients with type 2 diabetes.
BACKGROUND Fructooligosaccharides have been cl aim ed to lower fasting glycemia and serum total cholesterol concentrations , possibly via effects of short-chain fatty acids produced during fermentation . OBJECTIVE We studied the effects of fructooligosaccharides on blood glucose , serum lipids , and serum acetate in 20 patients with type 2 diabetes . DESIGN In a r and omized , single-blind , crossover design , patients consumed either glucose as a placebo ( 4 g/d ) or fructooligosaccharides ( 15 g/d ) for 20 d each . Average daily intakes of energy , macronutrients , and dietary fiber were similar with both treatments . RESULTS Compliance , expressed as the proportion of supplements not returned , was near 100 % during both treatments . Fructooligosaccharides did not significantly affect fasting concentrations ( mmol/L ) of serum total cholesterol ( 95 % CI : -0.07 , 0.48 ) , HDL cholesterol ( -0.04 , 0.04 ) , LDL cholesterol ( -0.06 , 0.34 ) , serum triacylglycerols ( -0.21 , 0.44 ) , serum free fatty acids ( -0.08 , 0.04 ) , serum acetate ( -0.01 , 0.01 ) , or blood glucose ( -0.37 , 0.40 ) . CONCLUSIONS We conclude that 20 d of dietary supplementation with fructooligosaccharides had no major effect on blood glucose , serum lipids , or serum acetate in patients with type 2 diabetes . This lack of effect was not due to changes in dietary intake , insufficient statistical power , or noncompliance of the patients
However , it can significantly decrease postintervention and reduction data of FPG , FI , HbA1c , and HOMA-IR .
Heterogeneity was eliminated by subgroup analysis according to baseline BMI .
There was no significant difference in the amelioration of QUICKI between the ITC and control groups .
However , the difference was statistically significant and the heterogeneity was eliminated after subgroup analysis according to intakes of ITC .
Conclusion Supplementation of ITC can ameliorate IR in T2DM , especially in obese T2DM patients , but the effects are controversial in obese patients
Background Insulin resistance ( IR ) is a physiological condition related to type 2 diabetes mellitus ( T2DM ) and obesity , which is associated with high blood insulin and glucose .
Inulin-type carbohydrate ( ITC ) is a kind of fermentable fructan that can reduce glucose and ameliorate IR in an animal model , but the effect in clinical trials is controversial .
Objective The authors conducted a systematic literature review to evaluate the effect of ITC supplementation in ameliorating IR in T2DM and obese patients .